Clinical trial · Interventional
A Study of Local Envafolimab Injection Combined With Chemotherapy in Non-small Cell Lung Cancer
A Single-arm, Exploratory Clinical Trial Investigating the Efficacy of Local Envafolimab Injection Under Fiberoptic Bronchoscopy Combined With Chemotherapy in Non-small Cell Lung Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of this single-arm, exploratory clinical study is to evaluate the safety and efficacy of local injection of envafolimab combined with chemotherapy in the first-line treatment of non-small cell lung cancer (NSCLC) patients, and to observe the changes of immune cells in the local immune microenvironment before and after immunotherapy, in order to find new indicators for immunotherapy evaluation.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| NSCLC | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Envafolimab Injection | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- envafolimab plus chemotherapy
- description
- Local injection of Envafolimab 5mg/kg plus platinum-based chemotherapy under fiberoptic bronchoscopy, Q2W.
- interventionNames
- Drug: Envafolimab Injection
Primary outcomes (3)
- measure
- Overall Survival(OS)
- timeFrame
- Up to 2 years
- description
- OS is defined as the time from randomization to death due to any cause.
- measure
- Objective Response Rate(ORR)
- timeFrame
- Up to 2 years
- description
- ORR is the proportion of subjects with complete response (CR) or partial response (PR), based on RECIST v1.1
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * 1\. The subjects volunteered to participate in the study, signed the informed consent form, and had good compliance; * 2\. ECOG≤2 ; * 3.Life expectancy of ≥12 weeks； * 4.Age ≥18 years; * 5\. Diagnosed by histological examination and/or cytology examination, and imaging evaluation (refer to RECIST 1.1) for advanced central NSCLC; * 6\. He had not received systemic chemotherapy previously. * 7.Had at least one measurable tumor lesion according to RECIST v1.1；That is, in CT or MRI detection, the longest diameter of a single lesion is ≥10mm, or the lymph node is pathologically enlarged, and the short diameter of a single lymph node on CT scan is ≥15mm； * 8.Have adequate organ function。 Exclusion Criteria: * 1.This study was conducted five years prior to the initiation of treatment or concurrently with other malignant tumors. * 2\. Have family history of cancer. * 3.had previously undergone any form treatment, such as surgery, chemotherapy, radiation therapy, etc. * 4.Only individuals experiencing grade 1 or higher unmitigated toxic effects (excluding alopecia and fatigue) resulting from previous therapies were eligible for enrollment; neurologic toxicity needed to return to grade 1 or lower or baseline before participation. * 5.Subjects with severe and/or uncontrollable disease progression； * 6.Human immunodeficiency virus (HIV) infection or known acquired immunodeficiency syndrome; * 7.Pregnant or lactating women; * 8.Other conditions considered unsuitable for this study by the investigator.
References
Publications (0)
Data not yet available